Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175269
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rodríguez Molinero, Alejandro | - |
dc.contributor.author | Pérez López, Carlos | - |
dc.contributor.author | Gálvez Barrón, César | - |
dc.contributor.author | Miñarro Alonso, Antonio | - |
dc.contributor.author | Macho, Oscar | - |
dc.contributor.author | López, Gabriela F. | - |
dc.contributor.author | Robles, Maria Teresa | - |
dc.contributor.author | Dapena, María Dolores | - |
dc.contributor.author | Martínez, Sergi | - |
dc.contributor.author | Rodriguez, Ezequiel | - |
dc.contributor.author | Collado Pérez, Isabel | - |
dc.contributor.author | COVID-19 research group of CSAPG | - |
dc.date.accessioned | 2021-03-17T15:16:44Z | - |
dc.date.available | 2021-03-17T15:16:44Z | - |
dc.date.issued | 2021-01-05 | - |
dc.identifier.issn | 2352-7714 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175269 | - |
dc.description.abstract | Background: Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement. Methods: Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). Patients admitted consecutively were included and followed until discharge or up to 30 days of admission. A sub-cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48 h after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders. Results: There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48 h of treatment, was not significantly different between groups (tocilizumab: −0.04; control: 0.09; p = 0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test: p = 0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; p = 0.990). Conclusions: We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48 h of treatment, or time to discharge. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.onehlt.2021.100214 | - |
dc.relation.ispartof | One Health, 2021, vol. 12 | - |
dc.relation.uri | https://doi.org/10.1016/j.onehlt.2021.100214 | - |
dc.rights | cc-by-nc-nd (c) Rodríguez Molinero, Alejandro et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es | - |
dc.source | Articles publicats en revistes (Genètica, Microbiologia i Estadística) | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | Coronavirus | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Coronaviruses | - |
dc.title | Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 706771 | - |
dc.date.updated | 2021-03-17T15:16:44Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33426262 | - |
Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
706771.pdf | 1.45 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License